
NYSE:KVUE
This summary was created by AI, based on 2 opinions in the last 12 months.
Kenvue (KVUE-N) is viewed as a solid choice for investors seeking steady performance, often being characterized as a 'classic steady Eddie'. Analysts appreciate the company's essential brands, which consumers rely on daily, and note that recent headlines, such as the Tylenol controversy involving a political figure, have contributed to a dip in stock price, creating a potential buying opportunity. The anticipated acquisition by KMB is seen positively, with expected benefits from multiple expansions and heightened interest in the stock due to spinoff dynamics. While the stock might not be the most exciting in terms of market performance, it is expected to deliver stability and yield at 4.78%, making it an interesting long-term hold.
Quality, essential brands we love and use daily. Attracted by spinoffs, as they tend to attract interest. Tylenol controversy from Trump pushed price down. Generic brands don't affect many of their products. Attractive multiple compared to PG and CL.
Likes the deal with KMB, which should close sometime next year. Multiple should expand. Not impacted by AI as far as he can tell ;) Yield is 4.78%.
Consumer staples are outperforming in the last few days, and that speaks to the advantage of having a balanced portfolio. Companies like KHC, UL, KVUE, and Nestle. It's not that they won't be affected (their costs would go up), but they're far less cyclical than other businesses. Earnings will be much more stable. Earnings could fall 10%, but not 50%. Dividends will be sustained.
Companies like Unilever and Nestle are huge in NA, but huge globally as well.
Kenvue is a American stock, trading under the symbol KVUE (previously KVUE-N on Stockchase) on the New York Stock Exchange (KVUE). It is usually referred to as NYSE:KVUE or KVUE
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on KVUE (previously KVUE-N on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Kenvue.
Kenvue was recommended as a Top Pick by Martin Cobb, ASIP on 2026-07-16. Read the latest stock experts ratings for Kenvue.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Kenvue.
Kenvue is followed by 15 investors on Stockchase and is a trending stock that is worth watching.
On 2026-09-02, Kenvue (KVUE) stock closed at a price of $19.13.
Being acquired by KMB. Multiple's in low teens. Classic steady Eddie. Dull and boring, but good to have in your portfolio.